<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01686048</url>
  </required_header>
  <id_info>
    <org_study_id>Ambrosia</org_study_id>
    <nct_id>NCT01686048</nct_id>
  </id_info>
  <brief_title>The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meir Medical Center</source>
  <brief_summary>
    <textblock>
      Ambrosia is known for its allergenicity in the USA causing hay fever and asthma. Israel has&#xD;
      always been considered &quot;clean&quot; of Ambrosia but over the past years growth of Ambrosia plants&#xD;
      has been detected in several locations in Israel.&#xD;
&#xD;
      In the proposed study, patients referred for routine allergic evaluation will also be skin&#xD;
      tested with Ambrosia allergens, in addition to their regular prick skin tests with all other&#xD;
      airborne allergens.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Asthma</condition>
  <condition>Allergic Conjunctivitis</condition>
  <condition>Atopic Dermatitis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients refered for allergic evaluation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with allergic rhinitis, asthma, allergic conjunctivitis or atopic dermatitis&#xD;
             who undergo prick skin tests with airborne allergens&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arnon Goldberg, M.D., Allergy and Clinical Immunology Unit, Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2012</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Meir Medical Center</investigator_affiliation>
    <investigator_full_name>Arnon Goldberg</investigator_full_name>
    <investigator_title>Head, Allergy and Clinical Immunology Unit</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Asthma</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01686048
org study id: Ambrosia
nct id: NCT01686048
lead sponsor: 
Ambrosia is known for its allergenicity in the USA causing hay fever and asthma. Israel has
      always been considered "clean" of Ambrosia but over the past years growth of Ambrosia plants
      has been detected in several locations in Israel.

      In the proposed study, patients referred for routine allergic evaluation will also be skin
      tested with Ambrosia allergens, in addition to their regular prick skin tests with all other
      airborne allergens.
observational model: Case-Only
time perspective: Prospective
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
facility: 
country: Israel
responsible party type: Principal Investigator
investigator affiliation: Meir Medical Center
investigator full name: Arnon Goldberg
investigator title: Head, Allergy and Clinical Immunology Unit
mesh term: Rhinitis
mesh term: Asthma
mesh term: Rhinitis, Allergic
mesh term: Conjunctivitis
mesh term: Conjunctivitis, Allergic
mesh term: Dermatitis